Agilvax teams with Humabs BioMed on vaccine development; IDRI nets $4M from BARDA for adjuvant hub;

> New Mexico's Agilvax and Switzerland's Humabs BioMed have agreed to collaborate on vaccine development. Release

> IDRI has received $4 million from the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to develop an adjuvant manufacturing hub. Release

> Wellcome Trust and the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) have released guidelines for fast-tracking Ebola vaccine development. More

> GlaxoSmithKline ($GSK) has granted $350,000 to the International AIDS Vaccine Initiative (IAVI) to support implementation of the Human Vaccines Project, a public-private partnership looking to address key challenges in vaccine development. Release

> The seasonal flu vaccine induces antibodies that can protect against H7N9 avian influenza, a study has found. Report

> A new study has found GlaxoSmithKline's ($GSK) HPV vaccine Cervarix highly effective against multiple cancer-causing strains. More

And Finally... Scientists have used genetically engineered algae to produce a potential malaria vaccine candidate. More

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.